Atherosclerosis
Volume 199, Issue 1 , Pages 147-153 , July 2008

The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients

  • Blai Coll

      Affiliations

    • Centre de Recerca Biomèdica, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • Servei de Medicina Interna, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • Both authors contributed equally.
    • Corresponding Author InformationCorresponding author. Centre de Recerca Biomèdica, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain. Tel.: +34 977 310 300; fax: +34 977 319 984.
    • ,
  • Anna Cabre

      Affiliations

    • Unitat de Recerca Lípids i Arteriosclerosi, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • Both authors contributed equally.
    • ,
  • Carlos Alonso-Villaverde

      Affiliations

    • Servei de Medicina Interna, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • ,
  • Iolanda Lazaro

      Affiliations

    • Unitat de Recerca Lípids i Arteriosclerosi, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • ,
  • Gerard Aragonés

      Affiliations

    • Centre de Recerca Biomèdica, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • ,
  • Sandra Parra

      Affiliations

    • Servei de Medicina Interna, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • ,
  • Josefa Girona

      Affiliations

    • Unitat de Recerca Lípids i Arteriosclerosi, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • ,
  • Lluis Masana

      Affiliations

    • Servei de Medicina Interna, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain
    • Unitat de Recerca Lípids i Arteriosclerosi, Universitat Rovira i Virgili, 43201 Reus, Tarragona, Spain

Received 23 May 2007 ,Revised 18 September 2007 ,Accepted 24 September 2007.

References 

  1. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med. 2005;118(Suppl. 2):23S–28S
  2. Grinspoon SK, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62
  3. Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep. 2005;2:132–139
  4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP final report. Circulation 2002; 106:3143–3421.
  5. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132–137
  6. van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol. 2006;47:1117–1123
  7. Baril L, Beucler I, Valantin MA. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS. 2001;15:415–417
  8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58
  9. Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS. 2002;16:1785–1789
  10. Coll B, Parra S, Alonso-Villaverde C, et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine. 2006;34:51–55
  11. Wootan MG, Bernlohr DA, Storch J. Mechanism of fluorescent fatty acid transfer from adipocyte fatty acid binding protein to membranes. Biochemistry. 1993;32:8622–8627
  12. Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274:1377–1379
  13. Layne MD, Patel A, Chen YH, et al. Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J. 2001;15:2733–2735
  14. Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. PNAS. 2006;103:6970–6975
  15. Cabre A, Lazaro I, Girona J, et al. Fatty acid binding protein-4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 2007;195:e150–e158
  16. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004;110:2204–2209
  17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  18. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598
  19. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003
  20. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab. 2000;11:175–180
  21. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428
  22. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46:2347–2355
  23. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. MCP-1 release is higher in visceral than subcutaneous human adipose tissue. Implication of macrophages resident in the adipose tissue. J Clin Endocrinol Metab. 2005;25:2282–2289
  24. Boord JB, Maeda K, Makowski L, et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22:1686–1691
  25. Yeung DCY, Xu A, Cheung CWS, et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:1796–1802
  26. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to New Targets Study. Lancet. 2006;368:919–928
  27. Zhang B, Macnaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clinical Endocrinol Metabol. 1999;84:4274–4277
  28. Llaverias G, Noe V, Penuelas S, et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun. 2004;318:265–274
  29. Karpisek M, Stejskal D, Kotolova H, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest. 2007;37:637–642
  30. Coort SLM, Coumans WA, Bonen A, et al. Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. J Lipid Res. 2005;46:1295–1302

PII: S0021-9150(07)00595-3

doi: 10.1016/j.atherosclerosis.2007.09.032

Atherosclerosis
Volume 199, Issue 1 , Pages 147-153 , July 2008

Article Tools

* Image Usage & Resolution